Fruquintinib in patients with metastatic colorectal cancer failed in previously bevacizumab-based therapy: A monocentric retrospective study.

被引：0
|
作者：
Gu, Xiaoqiang [1 ]
机构：
[1] Shanghai Univ Tradit Chinese Med, LongHua Hosp, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15555
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Body fatness and bevacizumab-based therapy in metastatic colorectal cancer
    Renehan, Andrew G.
    GUT, 2010, 59 (03) : 289 - 290
  • [2] BEVACIZUMAB plus CHEMOTHERAPY BEYOND FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS PREVIOUSLY TREATED WITH BEVACIZUMAB-BASED THERAPY: TML STUDY SUBGROUP FINDINGS
    Andre, Thierry
    Jose Maria, Vieitez
    Bouche, Olivier
    Bennouna, Jaafar
    Sastre, Javier
    Alonso-Orduna, Vicente
    Arnold, Dirk
    Osterlund, Pia
    Greil, Richard
    Van Cutsem, Eric
    von Moos, Roger
    Reyes-Rivera, Irmarie
    Makrutzki, Martina
    Kubicka, Stefan
    ANNALS OF ONCOLOGY, 2012, 23 : 14 - 14
  • [3] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
    Xu, Ran
    Xu, Chen
    Liu, Chuntong
    Cui, Can
    Zhu, Jing
    ONCOTARGETS AND THERAPY, 2018, 11 : 8605 - 8621
  • [4] Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study
    Artaç M.
    Coşkun H.Ş.
    Dane F.
    Karabulut B.
    Korkmaz L.
    Karaağaç M.
    Çabuk D.
    Karabulut S.
    Faruk Aykan N.
    Doruk H.
    Avcı N.
    Turhal N.S.
    Journal of Gastrointestinal Cancer, 2016, 47 (3) : 264 - 272
  • [5] An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
    Kiss, David
    Machackova, Tana
    Souckova, Kamila
    Fabian, Pavel
    Krepelkova, Iveta
    Svoboda, Marek
    Kiss, Igor
    IN VIVO, 2021, 35 (05): : 2809 - 2814
  • [6] Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
    Manzoni, M.
    Rovati, B.
    Ronzoni, M.
    Loupakis, F.
    Mariucci, S.
    Ricci, V.
    Gattoni, E.
    Salvatore, L.
    Tinelli, C.
    Villa, E.
    Danova, M.
    ONCOLOGY, 2010, 79 (3-4) : 187 - 196
  • [7] Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments
    Quesada, Stanislas
    Chatelet, Chloe
    BULLETIN DU CANCER, 2024, 111 (12) : 1084 - 1085
  • [8] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [9] Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer A meta-analysis
    Ma, Hongbo
    Wu, Xiaoli
    Tao, Miaomiao
    Tang, Nan
    Li, Yanyan
    Zhang, Xianquan
    Zhou, Qi
    MEDICINE, 2019, 98 (50)
  • [10] Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy
    Demircan, Nazim Can
    Dane, Faysal
    Ozturk, Mehmet Akif
    Babacan, Nalan Akgul
    Besiroglu, Mehmet
    Kaya, Serap
    Ercelep, Ozlem
    Tanrikulu, Eda
    Halil, Suleyman
    Koca, Sinan
    Alan, Ozkan
    Hasano, Rahip
    Yumuk, Perran Fulden
    JOURNAL OF BUON, 2019, 24 (04): : 1494 - 1500
12345